CSDCO calls meeting of makers of 19 older FDCs to examine their rationality
New Delhi: With an aim to understand the rationality of certain older Fixed Dose Combination (FDC) molecules in the market, The Central Drug Standard Control Organisation (CDSCO) has invited the stakeholders concerning 19 such drugs to come and attend the meeting in this regard.
The meeting of the expert committee with the stakeholders was meant to happen on the 29th and 30th of December, 2021 however had to be postponed because the companies advised that attending the meeting would be difficult due to the year-end holidays.
On 6th January 2022 Deputy Drugs Controller of India Sanjeev Kumar published a new notice informing about the rescheduling of meeting which will now take place on 27th and 28th of January, 2022. CDSCO expert committee has invited the concerned stakeholders for the video conference
Stakeholders must give information on the rationale, safety, and efficacy of such Fixed-Dose Combination FDCs in the suggested format for the aforesaid conference to assess the status of Fixed-Dose Combination medications.
There are 19 FDCs on the list for which CDSCO has requested information. Nimesulide with paracetamol dispersible pills, Paracetamol, Phenylephrine, Caffeine combination, Pholcodine and Promethazine combination, imipramine and Diazepam combination, Salbutamol and Bromhexine combination, are among the medications on the list.
This is in line with the Supreme Court of India's judgments dated 15.12.2017 and 14.02.2019, which stated that the Central Government may, if it so desires, conduct a de novo investigation into whether fixed-dose combinations licensed before 1988 should be the subject of a notification under Section 26A of the Drugs and Cosmetics Act, 1940. (23 of 1940).
The Pharmaceuticals and Cosmetics Act of 1940, Section 26A, gives the Central Government the authority to regulate, restrict, or prohibit the manufacture, distribution, and sale of drugs and cosmetics in the public interest.
Section 26A of the Drugs and Cosmetics Act, 1940, stated, "Without prejudice to any other provision contained in this Chapter, if the Central Government is satisfied that the use of any drug or cosmetic is likely to involve any risk to human beings or animals, or that any drug does not have the therapeutic value claimed or purported to be claimed for it or contains ingredients and in such quantity for which there is no therapeutic justification and that in the public interest it is necessary or expedient so to do, then, that Government may, by notification in the Official Gazette, regulate, restrict or prohibit the manufacture, sale or distribution of such drug or cosmetic."
Earlier the CDSCO had also asked the companies to submit data on rationality of these older FDCs
Also Read: CDSCO asks stakeholders to submit data on rationality, safety, & efficacy of older FDCs
In follow-up the CDSCO has now planned a meeting of the stakeholders. According to the fresh notice, if the stakeholder does not appear for the meeting, the committee has the right to make its decision based on available information. As per the annexure, participation in the conference should be confirmed through mail at fdc@cdsco.nic.in along with a PowerPoint presentation, mobile number, email id, serial number of the FDC, before the 24th of this month.
To read the full notice click on the following link
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.